FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

FDA Approves Rextovy as New OTC Naloxone Nasal Spray

The FDA has approved Rextovy, a 4 mg naloxone hydrochloride nasal spray, for over-the-counter (OTC) emergency treatment of opioid overdose, allowing direct purchase without a prescription. This action, announced on June 16, 2026, broadens access to a life-saving medication and aligns with the Great American Recovery Initiative to address the U.S. addiction crisis. Rextovy, developed by Amphastar Pharmaceuticals, Inc., offers an additional option to reverse opioid overdose effects. While overdose deaths have decreased since the first OTC naloxone approval in 2023, they remain a significant public health issue, primarily driven by synthetic opioids like fentanyl.

• The FDA's approval of Rextovy as an over-the-counter intranasal naloxone product significantly enhances public access to emergency opioid overdose treatment. This allows consumers to purchase the 4 mg naloxone hydrochloride nasal spray directly from various retail outlets without a prescription, empowering individuals without medical training to administer immediate, life-saving intervention. This initiative is a key component of the federal strategy to combat the ongoing opioid crisis in the U.S.
• Rextovy contains the same active ingredient as other approved naloxone nasal sprays, providing a critical tool for rapidly reversing the effects of opioid overdose. The introduction of this additional OTC formulation is expected to stimulate market competition, potentially leading to reduced costs and offering more diverse sourcing options for this essential medication. The FDA emphasizes its commitment to ensuring broad availability of nonprescription naloxone products to save lives.
• Despite a reported decrease in overdose deaths since the initial OTC naloxone approval in 2023, drug overdose, particularly from synthetic opioids like fentanyl, persists as a major public health concern in the U.S. Rextovy is safe for use even when the presence of opioids is uncertain. The product packaging includes clear, pictorial instructions, highlighting the crucial step of calling 911 immediately after administering the first dose to ensure comprehensive post-overdose care.

Rextovy's OTC Approval: Broadening Access to Life-Saving Care

The opioid overdose crisis continues to disproportionately affect discrete, high-risk populations where gaps in treatment access, harm reduction infrastructure, and targeted intervention remain pronounced. Emerging literature highlights both established vulnerable groups and previously underserved subpopulations where unmet clinical and programmatic needs are driving excess morbidity and mortality.

• Recently incarcerated people who inject drugs (PWID): Among 1,648 recently incarcerated PWID across 20 large U.S. cities, 28% reported an unmet need for medications for opioid use disorder (MOUD) and 39% reported a non-fatal opioid-involved overdose in the past 12 months. Those with unmet MOUD need were 1.4 times as likely to report a non-fatal overdose (50% vs. 35%), with homelessness (aPR=1.43) and residence in the Midwest (aPR=1.18) as significant compounding factors.

• Individuals with co-occurring psychiatric conditions: In a New York State Medicaid cohort of 523,885 adults receiving psychiatric services, OUD prevalence was 8.1%, with 7.7% of that group experiencing an opioid overdose within the study year. Overdose risk was markedly elevated among those with suicidality (34.0%, AOR=6.82) and economic instability (16.0%, AOR=2.57), with additional elevated OUD rates in individuals with PTSD (15.7%, AOR=2.34), bipolar disorder (14.9%, AOR=2.29), and anxiety disorders (11.3%, AOR=2.18).

• Migrants and populations outside harm reduction programs: Data from 21 harm reduction sites in Myanmar (2014–2025) capturing 155,875 clients revealed that three-quarters of 3,472 verified opioid overdoses occurred in persons not enrolled in harm reduction programs, with pooled incidence among people who inject drugs at 16.8 per 1,000 person-years. Migrants were significantly less likely to have accessed services in the year preceding overdose (aPR=0.82, 95% CI 0.68–0.98), identifying them as a structurally underserved subpopulation requiring tailored outreach and referral pathways.

• PWID with high-burden comorbidities: Approximately 49.2% of PWID participants had experienced an opioid overdose at some point; opioid dependence (aOR=4.4), suicidal ideation (aOR=1.8), alcohol use disorder (65.8%), and depressive symptoms (58.3%) were prevalent comorbidities substantially amplifying overdose risk within this group.

• Rural and racially/ethnically diverse populations: OUD rates were disproportionately elevated among rural residents (9.9%), American Indians (13.2%, AOR=1.43), and Hispanics (9.6%, AOR=1.29). Rural communities were also identified as furthest from naloxone saturation thresholds, compounding geographic inequities in overdose response capacity.

• Patients with stimulant use disorder (StUD): With no FDA-approved pharmacotherapy for StUD, this population carries significant unmet treatment need. Among 1,481 Veterans Health Administration patients with StUD receiving contingency management (CM), those treated were 41% less likely to die over a one-year follow-up period (aHR=0.59, 95% CI 0.36–0.95), representing the first real-world evidence linking CM to reduced mortality in this indication.

• Buprenorphine-nonadherent Medicaid beneficiaries: Nearly half of Medicaid beneficiaries with OUD exhibited varying degrees of nonadherence to buprenorphine within 180 days of treatment initiation. The continuously declining nonadherence group faced the highest risks: opioid overdose HR=1.92, all-cause hospitalization HR=1.71, and SUD-related hospitalization HR=2.01, alongside healthcare cost increases of up to $1,698 relative to adherent patients.

Addressing Key Challenges in Opioid Overdose Treatment

Current treatment approaches for opioid overdose — centered primarily on naloxone administration and harm reduction programming — face substantial systemic, pharmacological, and behavioral barriers that limit their real-world effectiveness. Despite numerous healthcare touchpoints, the majority of high-risk patients are not reached by existing interventions. Addressing these gaps requires coordinated action across prescribing practice, policy, public education, and emerging therapeutic development.

• Critically Low Naloxone Prescribing Rates: Only 1.5% of 138,108 high-risk commercially insured individuals were prescribed naloxone, meaning 98.5% (135,973 patients) went without a prescription despite extensive healthcare system contact — including 88,618 hospitalizations, 229,680 emergency department visits, 298,058 internal medicine visits, and 568,448 family practice visits. Naloxone is rarely prescribed proactively, and a prior diagnosis of opioid overdose alone was paradoxically associated with a decreased likelihood of receiving a naloxone prescription (OR 0.73; 95% CI 0.57–0.94).

• Illicitly Manufactured Fentanyl (IMF) Resistance to Standard Naloxone Dosing: The growing prevalence of IMF and its analogues in the illicit drug supply has significantly complicated overdose reversal. Growing evidence indicates that higher doses or multiple administrations of naloxone are required to fully reverse IMF-related toxicity, and long-acting synthetic opioids with high µ-opioid receptor affinity and slow receptor dissociation kinetics are particularly resistant to naloxone's effects. Drug overdose deaths in the U.S. exceeded 107,000 in 2023, with approximately 80,000 attributed to opioids alone.

• Healthcare System Implementation Failures: Emergency department implementation of evidence-based harm reduction strategies remains consistently challenging. Following Rhode Island's Levels of Care initiative, ED naloxone prescribing rates increased from only 1.5% to 28.7% — still a markedly low uptake. Fewer than half of patients treated for opioid overdose received behavioral counseling or referral to treatment, and 83% of high-risk inpatients had never previously received overdose education and naloxone distribution (OEND).

• Emergency Response Gaps and Legal Deterrents: Among overdose witnesses, only 43.1% called 911 and only 30.4% performed rescue breathing, despite naloxone being used in 62.7% of events. Potential legal consequences were cited as a major barrier to contacting emergency medical services by 42.3% of respondents, underscoring the need for policy reform alongside public education to facilitate appropriate overdose response.

• Prescribing Disparities Across Demographics and Geographies: Naloxone prescription rates are disproportionately lower among patients aged 30–44 years (OR 0.72) and those residing in the Midwest (OR 0.62) or West (OR 0.85). Most existing interventions disproportionately address White individuals in urban areas, leaving other populations with limited access. Additionally, Medicaid-covered naloxone fills are subject to monthly prescription fill limit policies in 10 state programs — covering 20% of the Medicaid population nationally — seven of which are located in states ranking among the top 10 for per-capita opioid prescribing rates.

• Public Stigma and Misconceptions Around Naloxone: Stigma remains a significant barrier to naloxone uptake: 51% of survey respondents believed that having naloxone available enables opioid misuse, and responses were evenly split on whether "naloxone is only necessary for people who abuse opioids." The perception that a reversal agent may enable patients with opioid use disorder to continue misuse without fear of fatal consequence further undermines prescriber willingness and community acceptance.

• Limitations in Virtual OEND Program Evaluation: The expanding landscape of virtual overdose education and naloxone distribution (OEND) programs is hindered by heterogeneity in study designs, outcome measures, scales, and measurement timepoints, making meaningful cross-study analysis of effectiveness difficult. Implementation and formal evaluation of virtual OEND programs remain limited, constraining evidence-based scale-up.

The Evolving Landscape of Opioid Overdose Treatment

Over the past five years, naloxone has remained the pharmacological cornerstone of opioid overdose reversal, yet significant gaps persist between its availability and its clinical deployment. Analysis of 148,966 emergency department (ED) visits for opioid overdose between August 2019 and April 2021 revealed that naloxone was prescribed within 30 days at only 7.4% of encounters — a rate markedly lower than the 48.9% epinephrine prescribing rate following anaphylaxis presentations, underscoring a critical missed intervention opportunity. A California mandate requiring naloxone co-prescribing produced a substantial post-implementation increase (from 104 to 6,031 ED naloxone prescriptions) and a concurrent reduction in opioid prescribing rates, yet yielded no statistically significant change in opioid overdose visits, hospitalizations, or 30-day mortality — indicating that prescribing access alone is insufficient to reduce overdose-related mortality at the population level. Provider-level data from 2025 further reflect this gap: while 90.9% of providers were aware of naloxone prescribing as a preventive strategy, only 72.1% reported willingness to prescribe, with barriers including unfamiliarity with naloxone's safety profile and the erroneous belief that prescribing may encourage continued nonprescribed opioid use.

The illicit drug supply, now heavily dominated by illicitly manufactured fentanyl (IMF) and its high-potency analogues, has directly driven shifts in naloxone dosing practice and formulation strategy. Multiple naloxone administration (MNA) rates in EMS-based studies ranged from 9% to 53%, with bystander-reported rates reaching as high as 89%, and three longitudinal analyses documented annual MNA rate increases of 26–43% (p < .001). In response, the FDA approved higher-dose naloxone formulations, and a 2022 survey of 1,152 patients entering opioid use disorder (OUD) treatment found that 35.9% preferred higher-dose formulations, with this preference significantly associated with recent suspected fentanyl exposure. Comparative route-of-administration data demonstrated that intranasal and intramuscular/intravenous naloxone achieved statistically equivalent success rates (82.54% vs. 80.39%, respectively), though intranasal administration required rescue doses 2.17 times more frequently (OR = 2.17; 95% CI: 1.53–3.09; p < 0.0001) and had a slightly longer onset of action. Pediatric prehospital data from 2025 confirmed that naloxone improved clinical status in 54.1% of activations and worsened it in only 0.2%, reinforcing its safety across age groups.

Beyond naloxone, the treatment landscape is expanding through both pharmacological innovation and systems-level interventions. Nalmefene — a higher-affinity, longer-acting opioid antagonist — had its injectable formulation reintroduced in 2022 and received FDA approval for an intranasal formulation in 2023, though professional bodies including the American College of Medical Toxicology and American Academy of Clinical Toxicology have recommended against its replacement of naloxone as the primary antidote pending comparative clinical trial data. Methocinnamox (MCAM), a novel pseudo-irreversible µ-opioid receptor antagonist, has demonstrated in nonhuman primate models the capacity to block the reinforcing effects of heroin, fentanyl, and carfentanil for up to two weeks following a single administration, with potency exceeding that of naloxone, naltrexone, and nalmefene for reversing buprenorphine and carfentanil effects. Biologics — including opioid-targeted monoclonal antibodies and vaccines — represent an emerging class capable of sequestering circulating opioids peripherally before CNS penetration, with patent activity accelerating over the past six years. At the systems level, medications for OUD (methadone, buprenorphine, naltrexone) remain critically underutilized, reaching only 25.1% of individuals with OUD in the US in 2022, despite evidence that MOUD reduces all-cause mortality risk by approximately 48% (adjusted HR 0.52; 95% CI: 0.42–0.63). Community-wide naloxone distribution programs have been associated with 25–46% lower opioid overdose mortality rates, and academic detailing interventions to support prescriber uptake have demonstrated cost-effectiveness at US$514 per QALY gained — well within conventional willingness-to-pay thresholds.

Rextovy's OTC Approval: A Critical Step in Opioid Overdose Response

The FDA's recent approval of Rextovy for over-the-counter availability marks a pivotal moment in the ongoing fight against the opioid epidemic. This move significantly broadens access to a critical, life-saving intervention, aligning with national efforts to empower communities and individuals in responding to opioid overdose emergencies. With potent synthetic opioids like fentanyl continuing to drive high mortality rates, the ability for laypersons to directly purchase and administer naloxone becomes an increasingly vital component of public health strategy.

Studies consistently demonstrate the effectiveness of community-based naloxone distribution and bystander intervention in preventing fatal overdoses. The availability of an OTC nasal spray simplifies administration, making it more accessible for individuals who may witness an overdose, whether in their social networks or broader community. This supports a shift towards a 'universal precautions' model, where naloxone is readily available not just to high-risk individuals, but to anyone who might encounter an overdose, including those on chronic opioid therapy or older adults who are often less likely to receive it.

However, the path forward is not without its challenges. Despite increased access, naloxone stigma—the perception that it is only for 'addicts'—remains a significant barrier to widespread possession and willingness to use. Furthermore, while a 4mg dose is effective, the rising prevalence of extremely potent synthetic opioids like carfentanil may sometimes necessitate multiple or higher doses for successful reversal, a factor that emergency services are increasingly encountering. Finally, while naloxone saves lives in the immediate term, it is crucial to remember that overdose reversal is an opportunity to initiate opioid use disorder (OUD) treatment. The current system often falls short in linking individuals to comprehensive psychosocial treatment and relapse prevention medications post-reversal, highlighting a persistent gap in addressing the underlying addiction.

Ultimately, Rextovy's OTC approval is a powerful step towards democratizing overdose response. Yet, its full potential will only be realized through sustained public education campaigns to combat stigma, continued research into optimal dosing for evolving opioid threats, and robust integration with long-term OUD treatment pathways.